Seng H. Cheng, Ph.D.
Dr. Seng Cheng, Ph. D., is Head of Research and Early Development of the Rare Diseases Division at Genzyme, a Sanofi Company. Dr. Cheng received his BSc, and PhD degrees in Biochemistry from the University of London, U.K. He trained as a postdoctoral fellow at the National Institute for Medical Research in London, U.K., in the field of tumor biology.
He was a Staff Scientist at Integrated Genetics Inc., and later joined Genzyme Corporation to work on several discovery projects including the structure and function of the cystic fibrosis transmembrane conductance regulator. As Group Vice President of Genetic Diseases Science at Genzyme, he also managed the development of novel gene delivery systems as well as translational research in genetic diseases, a number of which transitioned to clinical testing. Areas of focus included inherited metabolic, muscle, lung and neurodegenerative diseases. He has co-authored 245 research articles and reviews, and is a named co-inventor on 50 issued patents in the area of biotechnology. In his current position, he is responsible for directing the translational research and early clinical development activities in rare genetic diseases.